Get the Stockscreener App
32.17
2.69%
-0.89
After Hours:
32.17
Vaxcyte Inc stock is traded at $32.17, with a volume of 1.47M.
It is down -2.69% in the last 24 hours and up +7.23% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$33.06
Open:
$32.52
24h Volume:
1.47M
Relative Volume:
1.03
Market Cap:
$4.18B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-6.9935
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
-2.57%
1M Performance:
+7.23%
6M Performance:
-56.08%
1Y Performance:
-71.81%
1-Day Range:
$31.77
$32.88
1-Week Range:
$31.47
$33.67
52-Week Range:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
32.17 | 4.15B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte (PCVX) Initiates Coverage with Neutral Rating by Goldman Sachs | PCVX Stock News - GuruFocus
Polar Asset Management Partners Inc. Invests $378,000 in Vaxcyte, Inc. $PCVX - MarketBeat
Alliancebernstein L.P. Lowers Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Goldman Sachs initiates Vaxcyte stock coverage with Neutral rating By Investing.com - Investing.com Canada
TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling - uk.finance.yahoo.com
Vaxcyte, Inc. $PCVX Shares Sold by Woodline Partners LP - MarketBeat
Fred Alger Management LLC Has $844,000 Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Jones Financial Companies Lllp Has $6.27 Million Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Amundi Sells 63,416 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Stock Price, Quotes and Forecasts | NASDAQ:PCVX - Benzinga
Alyeska Investment Group L.P. Sells 32,945 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Can Vaxcyte Inc. continue delivering strong returnsJuly 2025 Price Swings & Accurate Entry/Exit Alerts - Lancaster City Council
Cormorant Asset Management LP Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
What is Vaxcyte Inc. s 5 year growth outlook2025 Trading Recap & AI Driven Stock Reports - beatles.ru
Is Vaxcyte Inc.’s growth already priced inWeekly Stock Report & Fast Exit and Entry Trade Guides - beatles.ru
Allostery Investments LP Takes $1.21 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
First Light Asset Management LLC Makes New Investment in Vaxcyte, Inc. $PCVX - MarketBeat
What indicators show strength in Vaxcyte Inc.Weekly Investment Summary & Growth Oriented Trade Recommendations - Newser
Vaxcyte, Inc. $PCVX Stock Holdings Boosted by RA Capital Management L.P. - MarketBeat
What are Vaxcyte Inc.’s growth leversRate Hike & Daily Profit Maximizing Tips - خودرو بانک
What are Vaxcyte Inc.’s recent SEC filings showingNew Guidance & Daily Chart Pattern Signal Reports - خودرو بانک
Vaxcyte, Inc. shares rise 3.73% intraday after presenting at Cantor Global Healthcare Conference. - AInvest
Vaxcyte Inc. stock outlook for YEARJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Short interest data insights for Vaxcyte Inc.2025 Momentum Check & Fast Moving Stock Watchlists - Newser
Vaxcyte Inc. stock trend forecastGold Moves & Free Safe Entry Trade Signal Reports - Newser
Is Vaxcyte Inc. forming a bottoming base2025 Key Highlights & Risk Controlled Stock Alerts - Newser
Will Vaxcyte Inc. stock recover after earningsQuarterly Portfolio Report & Long-Term Safe Investment Ideas - خودرو بانک
Advanced analytics toolkit walkthrough for Vaxcyte Inc.Earnings Miss & High Conviction Investment Ideas - Newser
Is Vaxcyte Inc. stock technically oversoldMarket Trend Review & Proven Capital Preservation Tips - خودرو بانک
Paradigm Biocapital Advisors LP Purchases 273,694 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
How to forecast Vaxcyte Inc. trends using time seriesJuly 2025 Summary & Daily Price Action Insights - Newser
Multi factor analysis applied to Vaxcyte Inc.2025 Earnings Impact & Weekly Market Pulse Updates - Newser
How to interpret RSI for Vaxcyte Inc. stockJuly 2025 Catalysts & Consistent Income Trade Recommendations - Newser
Live market analysis of Vaxcyte Inc.Weekly Profit Report & Safe Entry Point Identification - Newser
Is Vaxcyte Inc. forming a reversal patternJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - Newser
Vaxcyte advances VAX-31 pneumococcal vaccine to final stage of infant study - Investing.com Canada
Visualizing Vaxcyte Inc. stock with heatmapsEarnings Miss & Advanced Swing Trade Entry Alerts - Newser
Analyzing Vaxcyte Inc. with risk reward ratio charts2025 Support & Resistance & Safe Swing Trade Setups - Newser
Vaxcyte shares rise 1.90% after-hours as VAX-31 Phase 2 study advances to final stage. - AInvest
Vaxcyte Says VAX-31 Pneumococcal Disease Study Advances to Final Stage - MarketScreener
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose - The Manila Times
Vaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal Disease - Quiver Quantitative
92% Disease Coverage: Vaxcyte's VAX-31 Could Become Broadest Pneumococcal Vaccine for Infants - Stock Titan
What recovery options are there for Vaxcyte Inc.2025 Top Gainers & High Conviction Investment Ideas - Newser
How to build a custom watchlist for Vaxcyte Inc.July 2025 Update & Community Supported Trade Ideas - Newser
Evaluating Vaxcyte Inc. with trendline analysisWeekly Profit Summary & Long Hold Capital Preservation Tips - Newser
How institutional ownership impacts Vaxcyte Inc. stockMarket Sentiment Report & Verified Swing Trading Watchlist - Newser
What is the target price for Vaxcyte Inc. stock2025 Trading Volume Trends & Trade Opportunity Analysis Reports - khodrobank.com
Rafferty Asset Management LLC Has $4.98 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
How to manage a losing position in Vaxcyte Inc.July 2025 Price Swings & AI Based Buy and Sell Signals - Newser
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):